PALO ALTO, Calif--ALZA Corporation and U.S. Bioscience, Inc. have
announced the availability of Ethyol (amifostine), which was FDA
approved in December, 1995.
The agent is indicated to reduce the cumulative renal toxicity
associated with repeated administration of cisplatin (Platinol)
in patients with advanced ovarian cancer or non-small-cell lung
cancer. In these settings, the clinical data do not suggest that
the effectiveness of cisplatin-based chemotherapy regimens is
altered by use of Ethyol.
There are at present only limited data on the influence of Ethyol
on the efficacy of chemotherapy in other settings; therefore,
Ethyol should not be given to patients in other settings where
chemotherapy can produce a significant survival benefit or cure
(eg, certain malignancies of germ cell origin), except in the
context of a clinical study.
ALZA will be responsible for US sales and marketing of Ethyol.